Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Sidley Austin LLP
Sidley Austin LLP
X
LinkedIn
Trending Articles
AstraZeneca's Tagrisso obtains FDA approval for use in stage III NSCLC
Tagrisso reduced the risk of disease progression or death by 84% compared to placebo in the Phase III LAURA trial
Samsung Biologics debuts a series of monoclonal antibody development platforms
These solutions aim to optimise the efficacy of monoclonal antibody therapies, while also minimising the presence of charged variants
Flagship Pioneering launches gene therapy-focused biotech, Mirai Bio with $50m investment
The biotech has a machine intelligence-based open platform that aims to optimise a gene therapy's credentials, while also boosting the likelihood of its commercialisation
Quell and eXmoor join forces to manufacture and scale CAR-Treg therapies
The companies will combine their expertise to manufacture CAR-Treg cell therapies for clinical trials, with protocols put in place to support their scaling
Lonza to manufacture Vertex's CRISPR/Cas9 cell therapy, Casgevy
The one-time treatment will benefit patients with transfusion-dependent beta-thalassemia or sickle cell disease
Upcoming event
ISCC
15-18 October 2024 | Conference | Milan, Italy
See all
Related Content
Recruitment
Sidley announced new partner in global Life Sciences Practice
Subscribe now